Summary The prognostic significance of c-erbB-2 oncoprotein overexpression detected in tumours by immunocytochemical assays (ICAs) was investigated in 148 breast carcinomas. ICAs were performed under optimal technical conditions with frozen tissue sections and included automated immunoperoxidase technique and computer-assisted analysis (densitometry) of digitized coloured microscopic images. Results of quantitative ICAs (expressed in percentages of c-erbB-2-positive surfaces and mean optical densities) were correlated with the patients' follow-up in axillary lymph node-positive (N+) and node-negative (N-) subgroups of patients. Patients' follow-up ranged from 9 months (for the first death) to 101 months (for the 121 alive patients) with a 62.5 months mean overall follow-up. It was shown that marked c-erbB-2 immunocytochemical expression in tumours (cut-off point 35%) significantly correlated with the patients' poor overall survival in N+ and in N patients (Kaplan-Meier, log-rank test, P = 0.045 and P = 0.015). Also, marked c-erbB-2 immunohistochemical expression correlates with short disease-free (P = 0.005), recurrence-free (P = 0.048) and metastasis-free survival (P = 0.05) (Kaplan-Meier, log-rank test) in N+, but not in N-subgroups. It is concluded that in optimal conditions (automated and quantitative ICAs on frozen sections) c-erbB immunohistochemical expression is a significant prognostic indicator in terms of overall and disease-free survival. The c-erbB-2 protein prognostic significance is independent of node status in terms of overall survival, but not of disease-free survival.
patient survival
The prognosis of patients with operable breast cancers is extremely variable. Among the prognostic indices recognized as independent prognostic indicators, axillary nodal status is generally accepted to be the most important prognostic factor in patients with operable cancers. However, axillary lymph node invasion considered as a prognostic factor lacks sensitivity, since 30% of patients with pathologically negative nodes relapse and die within 10 years (McGuire et al, 1992) . This observation has led to a search for new accurate prognostic indicators in breast carcinomas.
Molecular biology studies have demonstrated the amplification and overexpression of some oncogenes in breast cancers. Slamon et al (1987 Slamon et al ( , 1989 showed that the c-erbB-2 gene was amplified in 27% of breast carcinomas. Further studies confirmed these findings, showing that c-erbB-2 amplification could be found in 10-40% of breast cancers (see review in Charpin et al, 1993; Ravdin et al, 1995) . Most of these studies revealed that c-erbB-2 amplification was correlated with an overexpression (mRNA) and with an increase of the synthesis of p185 kDa-encoded protein.
Amplification and overexpression of the c-erbB-2 oncogene detected by Southern and Northern blotting have been shown to correlate with the c-erbB-2 oncoprotein expression evaluated by Western blotting and immunocytochemistry (Slamon et al, 1987 (Slamon et al, , 1989 , suggesting that immunohistochemistry is suitable for evaluating the c-erbB-2 gene dysregulation in breast cancers.
The major practical relevance of c-erbB-2 amplification and overexpression with increased production of c-erbB-2 was first noted by Slamon et al (1987) . This report and the following one (Slamon et al, 1989) demonstrated that c-erbB-2 was significantly correlated with the clinical outcome of patients with metastatic axillary lymph nodes. Some further publications demonstrated that c-erbB-2 amplification and overexpression were significant prognostic indicators, independent of other current prognostic factors (Van de Vijver et al, 1988; Walker et al, 1989; Tandon et al, 1989; Wright et al, 1989; McCann et al, 1991; Paterson et al, 1991; Winstanley et al, 1991) . Other studies, however, could not demonstrate that c-erbB-2 amplification or overexpression did have prognostic significance (Shou et al, 1989; Heintz et al, 1990; Kury et al, 1990; Clark et al, 1991; McCann et al, 1991; Ravdin et al, 1995) . This controversy may arise from variations in the series size, technical procedures and/or statistical methods of analysis (Ravdin et al, 1995; Pauletti et al, 1996) . In particular, discrepancies in immunocytochemical studies may result from tissue fixation (Slamon et al, 1987 (Slamon et al, , 1989 Tandon et al, 1989; Clark et al, 1991; Paterson et al, 1991; Winstanley et al, 1991; Piffanelli et al, 1996) and from the lack of standardized means of evaluating immunostaining (Tandon et al, 1989; Charpin et al, 1993) .
In the present study, our goal was to investigate the prognostic significance in terms of overall and disease-free follow-up (8.4 were of ductal type (n = 96/148), whereas the remainder were of lobular type (n = 37/148, 25%) or of various histological types (n = 15/148, 10%), including mucinous (n = 3), tubular (n = 4), medullary (n = 5), papillary (n = 1), apocrine (n = 1) and cribriform mixed (n = 1). Ductal Immunostaining and image analysis Tissue Tissue fragments were sampled for immunostaining by a pathologist immediately after the intraoperative diagnosis performed on frozen sections. The size of the fragments frozen varied according to the tumour size (an average of 5 x 4 x 2 mm). The fragments were sampled in dense tumour areas, lacking grossly visible adipose tissue, promptly dipped in liquid nitrogen and stored at -80°C in the laboratory tumour library (tumours collected for prospective study since 1986). Immunodetections were perforrned on 5-,um-thick sections (cryostat Leica 3000, Rueil Malmaison, France).
Immunoperoxidase
Monoclonal (MAb) mouse anti-human c-erbB-2 oncoprotein (CB11) was purchased from Biogenex (Menarini, Chevilly Larue, France). Immunoperoxidase technique was performed using an automatic immunostaining device (Ventana, Medical System, Tucson, AR, USA) and Ventana kits (Strasbourg, France) (Grogan et al, 1993 (Grogan et al, , 1995 .
Image analysis
Immunostaining was analysed using an Axiophot microscope (Zeiss) and a 3 CCD Sony camera and then processed in an image analysis device (SAMBA 2005, Alcatel TITN, Grenoble, France) breast carcinomas, evaluated by automated (Ventana) immunoperoxidase on frozen sections: quantitation by computer-assisted analysis (SAMBA) of digitized coloured microscopic images (ordinate, % of patients; abscissa, % of immunostained surface vs counterstained surfaces) (Brugal et al, 1979) . The two parameters of the densitometric analysis, the percentages of positive immunostained surfaces (membrane and cytoplasm) vs counterstained surface and mean optical density (MOD), which depends upon the staining intensity (SAMBA arbitrary units scale: 0-255), were obtained as reported previously (Charpin et al, 1988 (Charpin et al, , 1992 (Charpin et al, , 1993 (Charpin et al, , 1994 (Charpin et al, , 1995a .
Statistical analysis
Analysis of disease-free and overall survival was performed using the Kaplan-Meier method. The difference between curves was evaluated with the Mantel-Cox test (or log-rank test) for censored survival or events observation. All computations were done with BMDP statistical software (University of California, Berkeley, CA, USA). The percentages of c-erbB-2 stained surface evaluated by image processing device were stratified and correlated with major events during the course of the disease (distant metastases or local recurrences) and with overall survival in order to define immunohistochemical thresholds of prognostic significance. The optimal c-erbB-2 protein cut-off point of positive surface endowed with prognostic significance was determined after statistical validation (Altman et al, 1994) . RESULTS c-erbB-2 distribution in tissue sections c-erbB-2 immunohistochemical expression was similar to that already observed in tumour cells (Charpin et al, 1992 (Charpin et al, , 1993 . All the invasive tumours were c-erbB-2 positive, but the immunostaining distribution was heterogeneous. Some tumours were markedly positive and others faintly positive (Figure 1) . However, the heterogeneity of c-erbB-2 expression essentially concerned the surfaces of immunostaining, whereas the intensity of staining was most often homogeneous and strong.
The variation in the c-erbB-2-positive surfaces on tissue sections is shown in the histogram in Figure 2 . C-erbB-2-positive surfaces evaluated by computer-assisted image analysis varied from 0.1% to 98% (mean = 34%, s.d. = 25%). Prognostic significance of c-erbB-2 oncoprotein overexpression 1671 c-erbB-2 immunohistochemical expression and patients' survival c-erbB-2 and overall survival (Table 1) c-erbB-2-Immunostained Surfaces (cut-off point 35%) significantly correlated with the patients' overall survival. Tumours with a large c-erbB-2-positive surface have a poorer survival than those with a small c-erbB-2-positive surface (Table 1) . When the entire patient series was stratified into node-positive (N+ = 66) and nodenegative (N-= 74) tumours, a significant c-erbB-2 (>35%) correlation with poor survival was observed in N-(P = 0.045) patients ( Figure 3A ) and in N+ (P = 0.015) patients ( Figure 3B ).
c-erbB-2 and disease-free survival (Table 2) Marked c-erbB-2 protein expression in tissue correlated (P= 0.015) with low disease-free survival, but only in N+ (P = 0.005) patients ( Figure 4A ) not in N-(P = 0.17) patients.
c-erbB-2 protein and recurrence-free survival (Table 3) Large c-erbB-2-positive surfaces also correlated (P = 0.048) with low recurrence-free survival in N+ patients ( Figure 4B ) but not in the N-subgroup (P = 0.23) of patients.
c-erbB-2 and metastasis-free survival (Table 4) Marked c-erbB-2 protein immunohistochemical expression correlated with metastasis-free survival in N+ patients (P = 0.05) ( Figure 4C ) but not in N-patients (P = 0.1).
DISCUSSION
The practical clinical relevance of c-erbB-2 overexpression is related to its prognostic significance in breast carcinomas (Slamon et al, 1987 (Slamon et al, , 1989 and to its value, recently reported, in predicting response to certain adjuvant therapies (Stal et al, 1995) . The prognostic value of the c-erbB-2 oncogene in breast carcinomas has been controversial, although now there is some evidence from the recent literature of its prognostic significance (Borg et al, 1990) . Amplification of c-erbB-2 has been reported as a significant predictor of both overall survival and relapse time in patients with breast cancers (Slamon et al, 1989; Tandon et al, 1989; Wright et al, 1989) or simply as a predictor of relapse (Van de Vijver et al, 1988; Press et al, 1993) .
Furthermore, c-erbB-2 amplification has been given a greater prognostic value than most currently used prognostic factors, including hormonal receptors in positive lymph node patients (Slamon et al, 1989 ) and some of the immunocytochemical studies showed similar results (Gusterson et al, 1988; McCann et al, 1991) . Some studies showed that c-erbB-2 overexpression was a marker of poor prognosis in N+ patients (Slamon et al, 1989; Tandon et al, 1989; Borg et al, 1990; Lipponen et al, 1993; Quenel et al, 1995) , while others identified c-erbB-2 as a marker of poor prognosis in the N-subgroup of patients (Paterson et al, 1991; Press et al, 1993) . In our study, c-erbB-2 immunodetectable overexpression correlated with poor overall survival in the N+ and Nsubgroups of patients, and with shorter disease-free survival only in N+ patients. However, the lack of statistical prognostic significance in terms of recurrence and metastasis-free survival in Npatients may result from fewer deaths in the N-subset compared with the N+ subset of patients.
Most of the discrepancies in the reports probably result at least partly from the lack of standardized methodologies, particularly for immunohistochemistry.
The amplification and overexpression are correlated with an increase in the encoded protein production detected by Western blots or immunoenzyme assays (Slamon et al, 1989; Quenel et al, 1995; Piffanelli et al, 1996) . Clark et al (1991) established that only the expression of five copy amplification could be detected on paraffin sections. The c-erbB-2 protein antigenic properties are stable and preserved even after formalin fixation and paraffin embedding. Southern, Northern and Western blots, as well as immunochemistry and fluorescence in situ hybridization (FISH), can be assessed in archival breast cancer specimens to detect c-erbB-2 amplification or overexpression, although FISH was recently found to be superior to all methodologies in fixed paraffinembedded tissue (Pauletti et al, 1996) . However, whatever the method used, fixation and paraffin embedding are responsible for a certain loss of antigenicity, as shown by the comparison of immunodetections performed on paraffin sections and on frozen sections (Tandon et al, 1989; Winstanley et al, 1991; Heatley et al, 1993 Quantitative immunocytochemistry has already been developed on a different system for c-erbB-2 ICAs (Baak et al, 1991; Bacus et al, 1990a, b; Charpin et al, 1992 Charpin et al, , 1993 Press et al, 1993) . In one study (Press et al, 1993) , the quantitative c-erbB-2 ICAs were related to the patients' follow-up. In this study, detection was performed on paraffin sections using a polyclonal antibody. It was shown that breast carcinomas with high overexpression of c-erbB-2 oncoprotein were associated in node-negative patients with a risk of recurrence 9.5 times greater than those with low c-erbB-2 expression (Press et al, 1993) . In our study, we obtained different results, although we also used computerized image analysis, probably because we used different antibodies and frozen-tissue samples. Quantitative immunochemistry, as assessed in our study, was developed to standardize immunohistochemical assays. The term, quantitative assay, only refers to quantitation of the immunostaining and cannot, therefore, pretend to quantify the antigens themselves, since immunohistochemical signals are the results of a series of amplification reactions that may not reflect the true receptor level within the samples.
In conclusion, using automated (Ventana device) and quantitative (SAMBA system) immunohistochemical assays on frozentissue samples of breast carcinomas, we showed that strong c-erbB-2 expression (cut-off point 35%) correlated with poorer 8-year overall survival in N+ and N-patients and shorter disease-free survival in N+ patients compared with weak c-erbB-2 immunoexpression.
